Protein Modification by Deamidation Indicates Variations in Joint Extracellular Matrix Turnover by Catterall, Jonathan B. et al.
Protein Modification by Deamidation Indicates Variations in
Joint Extracellular Matrix Turnover*□S
Received for publication, April 10, 2011, and in revised form, November 25, 2011 Published, JBC Papers in Press, December 16, 2011, DOI 10.1074/jbc.M111.249649
Jonathan B. Catterall‡, Ming F. Hsueh§, Thomas V. Stabler‡, Christopher R. McCudden‡, Michael Bolognesi¶,
Robert Zura¶, Joanne M. Jordan**‡‡, Jordan B. Renner§§, Sheng Feng¶¶, and Virginia B. Kraus‡§¶1
From the Departments of ‡Medicine, §Pathology, ¶Orthopaedic Surgery, and ¶¶Biostatistics and Bioinformatics, Duke University
Medical Center, Durham, North Carolina 27710 and the Thurston Arthritis Research Center and Departments of **Medicine,
‡‡Orthopaedics, and §§Radiology, University of North Carolina, Chapel Hill, North Carolina 27514
As extracellular proteins age, they undergo and accumulate
nonenzymatic post-translational modifications that cannot be
repaired. We hypothesized that these could be used to systemi-
callymonitor loss of extracellularmatrix due to chronic arthritic
diseases such as osteoarthritis (OA). To test this, we predicted
sites of deamidation in cartilage oligomeric matrix protein
(COMP) and confirmed, by mass spectroscopy, the presence of
deamidated (Asp64) and native (Asn64) COMP epitopes (mean
0.95% deamidated COMP (D-COMP) relative to native COMP)
in cartilage. An Asp64, D-COMP-specific ELISA was developed
using a newly created monoclonal antibody 6-1A12. In a joint
replacement study, serum D-COMP (p  0.017), but not total
COMP (p  0.5), declined significantly after replacement dem-
onstrating a joint tissue source for D-COMP. In analyses of 450
participants from the Johnston County Osteoarthritis Project
controlled for age, gender, and race, D-COMP was associated
with radiographic hip (p < 0.0001) but not knee (p  0.95) OA
severity. In contrast, total COMP was associated with radio-
graphic knee (p < 0.0001) but not hip (p  0.47) OA severity.
D-COMPwas higher in soluble proteins extracted from hip car-
tilage proximal to OA lesions compared with remote from
lesions (p  0.007) or lesional and remote OA knee (p < 0.01)
cartilage. Total COMP in cartilage did not vary by joint site or
proximity to the lesion. This study demonstrates the presence of
D-COMP in articular cartilage and the systemic circulation, and
to our knowledge, it is the first biomarker to show specificity for
a particular joint site. We believe that enrichment of deami-
dated epitope in hip OA cartilage indicates a lesser repair
response of hip OA compared with knee OA cartilage.
As proteins age they undergo nonenzymatic post-transla-
tionalmodifications.When aged proteins are intracellular, they
can be repaired or the protein replaced (1); however, in the
extracellular milieu, where no repair mechanisms exist, nonen-
zymatic modifications can accumulate in a time-dependent
manner in proteins whose turnover is slow. Accumulation of
these modifications in long lived proteins can potentially alter
both their structural and functional properties and provide
insights into turnover rates at which proteins are replaced
through net synthesis and degradation processes.
One form of nonenzymatic protein modification, deamida-
tion, is believed to be a mechanism of amino acid damage and
aging in numerous proteins (2) and a variety of tissues (2, 3).
Protein deamidation has been demonstrated to interfere with
protein function of interleukin-1 (4), soluble CD4 (5), angio-
genin (6), and Bcl-xL (4–7) and may also incite autoimmunity
(8). Nonenzymatic deamidation involves the conversion of Asn
toAsp or the conversion ofGln toGlu in a spontaneousmanner
without enzymes (3). During nonenzymatic Asn deamidation,
the side chain amine group is lost, causing formation of a suc-
cinimide ring. The succinimide ring is unstable and susceptible
to hydrolysis at the imide to form Asp in either an -Asp or
-Asp (isomerized) form depending upon which side of the
imide hydrolysis occurs. Things are further complicated as the
-carbon atom in the succinimide ring can undergo racemiza-
tion allowing the formation of both levorotatory and dextroro-
tatory optical isomers after hydrolysis. Similarly, Gln deamida-
tion involves formation of a ring structure (glutarimide), where
loss of the functional amine group leads to the formation of the
acidic residue Glu in again both the levorotatory and dextroro-
tatory forms of - or -Glu. Asn deamidation occurs roughly
twice as fast as Gln deamidation because of the less favorable
6-membered glutarimide ring structure. Particular hot spots
for deamidation are predicted to exist based upon factors such
as steric hindrance and protein context (3), as well as peptide
sequence (for instance, dipeptides that deamidate more readily
than others include Gly-Asn, Asn-Gly, and Gln-Gly (3)).
One of the tissues in the body most susceptible to accumula-
tion of nonenzymatic protein modifications is cartilage. This is
due to the slow turnover rate of many cartilage proteins; for
instance, cartilage aggrecan has a predicted half-life of 25 years
(9), whereas cartilage collagens have predicted half-lives of at
least 120 years (10, 11). Nothing at present is known of the
biological effects of these amino acid changes in cartilage, thus
representing a significant knowledge gap. We hypothesized
that the nonenzymaticmodifications that accumulate with car-
tilage aging could be used to systemically monitor onset and
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degree of extracellular matrix loss during osteoarthritis (OA).2
To test this hypothesis, we identified a novel protein modifica-
tion due to deamidation in cartilage oligomeric matrix protein
(COMP). COMP is a noncollagenous glycoprotein and a mem-
ber of the thrombospondin family of extracellular calcium-
binding proteins that was initially isolated from cartilage (12).
Although primarily expressed in cartilage, COMP is also
expressed in tendons, meniscus, and synovial membranes. The
carboxyl-terminal globular domain of COMP binds to colla-
gens I and II (13). The amino terminus of COMP oligomerizes
to form a pentamer of five identical subunits of 110 kDa (14),
creating a pore that is believed to bind chloride and vitamin D3
(15).
We raised novel monoclonal antibodies (mAb) and devel-
oped an ELISA that specifically distinguished and quantified
the deamidated form of the epitope from the total amount of
the epitope (amidated and deamidated). We further demon-
strated the presence of deamidated COMP (D-COMP) in artic-
ular cartilage and the systemic circulation, an enrichment of
this epitope specifically in hip articular cartilage, and a correla-
tion of this epitope in the systemic circulation with hip OA
severity.
EXPERIMENTAL PROCEDURES
Patient Samples—The Biomarker and Joint Arthroplasty
(BAJA) cohort provided serum samples drawn before or 6
months after either total hip or knee arthroplasty. A total of 14
subjects (9 male and 5 female) underwent total knee replace-
ment (n  10, six male and four female) or total hip replace-
ment (n  4, three male and one female) (Table 1). The overall
mean age was 63.4  13.2 years (59.6  13.8 years for men,
70.2  9.8 for women). The population was overweight with a
mean body mass index of 26.8  5.8 (27.8  5.6 for men and
25.0  6.6 for women). Samples were collected under approval
of the Institutional Review Board of Duke University.
The Johnston County OA Project (JoCo OA) provided
selected serum samples from 450 individuals at baseline evalu-
ation. The JoCo OA is an ongoing, community-based study of
knee and hip OA in African American and Caucasian residents
in a rural county in North Carolina. Details of this study have
been reported previously (16), and demographics are summa-
rized in Table 1. Briefly, this study involved civilian, noninsti-
tutionalized adults aged 45 years and older who resided in six
townships in Johnston County. Participants were recruited by
probability sampling, with oversampling of African Americans.
A total of 3,187 individuals completed a baseline clinical evalu-
ation from 1991 to 1997. Serum was collected for all partici-
pants at baseline. To allow for analyses of biomarkers in a sam-
ple balanced for gender and age, 450 participants were selected
with complete radiographic data at baseline to represent
roughly equal proportions of women (54%) and men (46%)
across a range of ages (see Table 1). A total of 39% of partici-
pants were African American. Individuals having radiographic
evidence of rheumatoid arthritis or other inflammatory
arthropathies in the knees or hips were not included in the
subsample. Participants completed bilateral anteroposterior
weight-bearing radiography of the knees with foot mat place-
ment and supine anteroposterior hip radiographs. Radiographs
were read, without knowledge of participant clinical or bio-
marker status by a single musculoskeletal radiologist (J. B. R.),
for overall radiographic severity by Kellgren-Lawrence (17)
(KL, score 0–4) of the knees and hips and for knee osteophyte
(score 0–3) and joint space narrowing (score 0–3) based on the
standardized Burnett atlas (18). Inter-rater reliability (compar-
ison of radiograph readings between J. B. R. and another radi-
ologist) and intra-rater reliability (comparison of radiograph
readings completed by J. B. R. at two separate times) were high
(weighted  for inter-rater reliability 0.9;  for intra-rater reli-
ability 0.9) (19). The studywas conducted under approval of the
Institutional Review Boards of the University of North Caro-
lina, Chapel Hill, and the Centers for Disease Control and
Prevention.
Waste articular cartilage specimens were obtained from ran-
domly selected total knee (n  15, mean age 66.5  8.9, 54–88
years) and total hip (n  11, mean age 77.3  11.3, 57–90
years) arthroplasties performed at Duke University Medical
Center to alleviate symptoms of OA. Patient characteristics are
summarized in Table 1. From each arthritic joint, cartilage was
harvested fromaround the lesion (lesion cartilage) and for com-
parison cartilage remote from the lesion (remote cartilage).
Nonarthritic control samples (n  11) were obtained from
National Disease Research Interchange (Philadelphia) or at the
time of reconstructive surgery for trauma from patients with-
out evidence of OA as determined by the surgeon and macro-
scopic inspection of the specimens. Samples were collected
under Duke Institutional Review Board approval as waste sur-
gical specimens.
Monoclonal Antibody Generation and Screening—To gener-
ate novel specific mAbs to investigate the predicted deamidated
epitopes in COMP, a COMP peptide, TFLKD64TVMEC, specific
for the deamidated epitope was used to immunize mice (A&G
2 The abbreviations used are: OA, osteoarthritis; BAJA, Biomarkers and Joint
Arthroplasty study; COMP, cartilage oligomeric matrix protein; Gdn-HCl,
guanidine HCl; JoCo OA, Johnston County Osteoarthritis Project; KL grade,
Kellgren-Lawrence grade of OA severity; mAb, monoclonal antibody; OPD,
o-phenylenediamine dihydrochloride; D-COMP, deamidated COMP.
TABLE 1
Cohort demographics
JoCo OA indicates a subset of 450 subjects from the Johnston County Osteoarthritis project.
BAJA JoCo OA Human cartilage
N (% female) 14 (36%) 450 (54%) 26 (42%)
Age mean  S.D. years (range) 63.4  13.2 (44–81) 58.88  9.62 (44–86) 71.3  10.0 (52–90)
No OA (N) 0 164 11
Hip OA without knee OA (N) 4 143 11
Knee OA without hip OA (N) 10 79 15
Hip and knee OA (N) 0 64 N/A
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Pharmaceutical, Columbia, MD). Antibody specificity was con-
firmed using a direct ELISA. Briefly, 96-well ELISA plates were
coated with COMP purified from hip cartilage (a gift from Dr. V.
Vilim)orBSAconjugatedto thedeamidation-specificCOMPpep-
tide (EITFLKD64TVMEC) or the nondeamidated native COMP
peptide (EITFLKN64TVMEC). For later screening experiments,
we synthesized two further constructswithdifferentpeptides cou-
pled to BSA as follows: one BSA-peptide construct contained the
native CELQETN42AALQ sequence, and the other coupled the
deamidatedCELQETD42AALQpeptide toBSA.TheCOMPpep-
tides (procured from AnaSpec, Fremont, CA), or COMP isolated
from cartilage, were coated in 0.1 M sodium carbonate/bicarbon-
ate coating buffer, pH 9.6, overnight at 4 °C. Plates were blocked
overnight with 5% w/v BSA in phosphate-buffered saline (PBS),
pH7.4, at 4 °Cbeforeexcessblockingbufferwasdiscarded, and the
plateswerewashedwith 0.05% v/v PBSwash buffer.Washedwells
were incubatedwithundilutedhybridoma supernatants overnight
at 4 °C. UnboundmAb was discarded and washed with 0.05% v/v
Tween 20 in PBS, pH7.4 (PBS/Tween), before addition of alkaline
phosphatase-conjugated anti-mouse antibody (Promega, Madi-
son, WI) and development with o-phenylenediamine dihydro-
chloride (OPD) substrate and detection at 450 nm.
Protein GAntibody Purification—The 6-1A12mAbwas pro-
duced in-house and purified using protein G-agarose (Thermo
Scientific, Rockford, IL) per the manufacturer’s instructions.
Briefly, the 6-1A12 hybridoma was grown in roller bottle cul-
ture in serum-free hybridoma medium (Sigma). The superna-
tants were collected, filtered through a 0.2-m filter, and con-
centrated 20-fold usingAmicon stirred ultrafiltration cells with
a 100-kDa molecular mass cutoff (Millipore, Billerica, MA).
Concentrated hybridoma medium was diluted 1:1 with 20 mM
sodium phosphate binding buffer, pH 7.0, before incubating
with protein G-agarose (1 ml of resin to 10 ml of diluted
hybridomamedium) overnight at 4 °Cwith gentlemixing. After
incubation, the protein G bead/hybridomamediumwas passed
into a column, and unbound proteins were washed from the
column with a further 5 ml of binding buffer; this wash was
collected in 1-ml aliquots, and a Bradford protein assay
(Thermo Scientific) was performed to confirm all unbound
protein was removed from the column. The 6-1A12 mAb was
eluted from the column with 0.1 M glycine buffer, pH 2.7, and
0.5-ml aliquots were collected. Each aliquot was neutralized
with 1 M Tris buffer, pH 7.4, to prevent mAb degradation. Frac-
tions containing mAb, as determined by a Bradford protein
assay, were pooled and dialyzed against PBS. A final mAb con-
centration was determined by Bradford protein assay (Thermo
Scientific), and the purified mAbs were aliquoted and stored at
80 °C until needed.
Extraction of Soluble Cartilage Matrix Proteins—Cartilage
was pulverized under liquid nitrogen and extracted in 4 M gua-
nidine HCl (Gdn-HCl) in sodium acetate buffer, pH 4.0, with
protease inhibitormixture (Sigma) at a ratio of 2ml ofGdn-HCl
extraction buffer per 1 g of wet weight cartilage. Cartilage was
extracted for 24 h at 4 °C with gentle mixing, followed by cen-
trifugation and collection of the supernatant. The remaining
cartilage was extracted a second time with Gdn-HCl extraction
buffer for a further 24 h. Both the first and second Gdn-HCl
extractions were combined and stored at 80 °C until needed.
A 200-l aliquot of the extract was buffer-exchanged on an
AKTA purifier 10 (GE Healthcare) using a HiTrap desalting
column (GE Healthcare) into PBS and stored at 80 °C. Pro-
teoglycan content was determined using the dimethylmethyl-
ene blue assay as described previously (20). Protein concentra-
tions were determined using the Bradford protein assay
(Thermo Scientific) to allow normalization of values.
To confirm the efficiency of our Gdn-HCl extraction proto-
col, we performed five sequential Gdn-HCl extractions in trip-
licate with brief water washes between two specimens, a hip
(non-OA, female, 69 years) and a knee (non-OA, male, 77
years). These analyses showed that the method we used rou-
tinely, that of two serial Gdn-HCl extractions, was highly effi-
cient and extracted between 99.3% (as estimated by glycosami-
noglycan) and 100.0% (as estimated by protein) of the soluble
proteins from cartilage (supplemental Table 1).
Mass Spectroscopic Identification of Deamidated COMP—
To prevent interference with downstream liquid chromatogra-
phy-mass spectroscopy (LC-MS/MS), residual Gdn-HCl was
removed by buffer exchanges into 50mMammoniumbicarbon-
ate, pH 7.8, using a HiTrap desalting column on an AKTA
HPLC system (GE Healthcare) followed by trypsin digestion.
The insoluble residue left after Gdn-HCl extraction was pre-
pared for LC-MS/MS by extensive washing of the cartilage with
50 mM ammonium bicarbonate, pH 7.8, for 3 days with five
buffer changes per day. After these extensive washes, the resid-
ual cartilage was weighed before direct trypsin digestion. After
trypsin digestion, all samples were subjected to shotgun pro-
teomics using LC-MS/MS as described previously (21). Briefly,
0.1% v/v rapigest (Waters) was added before reduction with 10
mM dithiothreitol at 80 °C for 15 min, alkylated with 20 mM
iodoacetamide for 30 min at room temperature, and digested
with proteomics grade trypsin (Promega, Madison, WI) over-
night at 37 °C. Prior to LC-MS/MS analysis, all samples were
resuspended in 20 l of 2% acetonitrile, 0.1% formic acid, pH
3.0. Chromatographic separation of peptide mixtures was per-
formed on a Waters NanoAcquity UPLC equipped with a
1.7-m BEH130 C18 75-m inner diameter  250-mm
reversed-phase column.Themobile phasewas 0.1% formic acid
in water (buffer A) and 0.1% formic acid in acetonitrile (buffer
B). MS analysis was performed on a Waters Synapt G2 mass
spectrometer, and label-free quantification and integration of
qualitative peptide identifications were performed using
Rosetta Elucidator (Version 3.3, Rosetta Inpharmatics, Seattle).
All raw LC-MS/MS data were subjected to chromatographic
retention time alignment using the PeakTeller algorithm.
Quantification of all signals in the precursor MS spectra was
performed by Elucidator by calculating peak volume (area
under curve). Datawere searchedwithMascot (Matrix Science,
Boston) against a human protein data base downloaded from
SwissProt appended with yeast alcohol dehydrogenase.
D-COMP Competitive ELISA—A competitive ELISA was
developed to determine whether the D-COMP epitope could
be measured using our mAbs in biological samples. Briefly,
coating concentrations were optimized (data not shown),
and binding plates were prepared by coating 96-well ELISA
plates with 6.5 g/ml D-COMP-specific BSA-peptide (BSA-
EITFLKD64TVMEC) in 0.02 M sodium carbonate coating
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buffer, pH 9.6, overnight at 4 °C. Plates were blocked for at least
2 h with 5% w/v BSA in PBS, pH 7.4, at 37 °C prior to use.
Protein G-purified 6-1A12 was diluted to 2 g/ml in protein
diluents (0.1% w/v BSA in PBS, pH 7.4) before addition of 80 l
of mAb to 80 l of either sample or standard in a low protein
bindingmixing plate for 30min at room temperature with gen-
tle mixing. The BSA-EITFLKD64TVMEC coupled construct
was used as a standard for the competitive assay and diluted for
a standard curve with a range of 0.1–10 g/ml. The binding
reaction was transferred to the coated capture plate, 60 l per
well, and incubated at room temperature for 1 h with gentle
mixing to allow freemAbbinding to the plate. Subsequent steps
were the same as for the direct ELISA described above.
D-COMP and Total COMP Sandwich ELISAs—The
D-COMP sandwich ELISA was based upon capture with
theD-COMP-specificmAb 6-1A12 and detectionwith 17-C10,
a mAb to total COMP (specificity for COMP irrespective of
deamidation state) (22). The method was the same as for the
competitive ELISA above with a few exceptions as follows:
96-well plates were coated with the 6-1A12 D-COMP-specific
mAb; samples or standard was diluted in 0.1% w/v BSA in PBS
as required prior to incubation of 50 l of sample or standard
overnight at 4 °C; and unbound sample was discarded and the
plate washed with PBS/Tween wash buffer before incubation
with the biotinylated 17-C10 total COMPdetectionmAb (a gift
from Dr. V. Vilim). Unbound 17-C10 was discarded, and the
plate was washed. Because of the lower levels of D-COMP, the
D-COMP ELISA sensitivity was increased using avidin poly-
horseradish peroxidase (poly-HRP, Thermo Scientific), added
for 30 min at room temperature with gentle mixing. Excess
avidin-HRPwas discarded; the platewaswashed, and signalwas
detected using tetramethylbenzidine (Sigma) reagent after
stopping with 2 M HCl and detection at 450 nm. Total COMP
was measured using the 16-F12 and 17-C10 mAbs as described
previously (22) with several modifications. For this project, we
used avidin-HRP and tetramethylbenzidine as the detection
system so that the total COMP and D-COMPmethods were as
similar as possible.
D-COMP Standard for ELISA—D-COMP concentrations by
sandwich ELISA were determined using a COMP standard
derived by pooling Gdn-HCl extracts from hip cartilage as fol-
lows: extracts from a 76-year-old normal hip specimen, and
extracts from lesioned and remote cartilage regions of 75-year-
old kneeOAand 72-year-old hipOA specimens (23). Themean
quantity of D-COMP in these samples was estimated as 0.95%
the quantity of total COMP based on the relative mean abun-
dance ofD-COMPand total COMPwithin the samemass spec-
trometry trace for each sample (% D-COMP in standard 
Asp64 peak intensity/Asn64 peak intensity100).
Western Blot Protocol—PBS-dialyzed Gdn-HCl cartilage
extract and precision plus prestained protein standards (5
g/well, Bio-Rad) were separated under reducing conditions
on a 10% SDS-PAGE. Proteins were transferred to a nitrocellu-
losemembrane. After transfer, themembranewas blockedwith
3% w/vmilk proteins for 2 h at room temperature. The blocked
membrane was incubated with 6-1A12 or 17-C10mAbs in PBS
1% w/v milk proteins overnight at 4 °C. Excess mAb was dis-
carded, and the membrane was washed with 0.1% v/v PBS/
Tween before incubation with anti-mouse HRP-conjugated
secondary antibody (Promega, Madison, WI) in 1% w/v milk
proteins for 30 min. Excess antibody was discarded, and the
membrane was washed before signal development with ECL
Plus reagent (GE Healthcare) using Hyperfilm ECL x-ray film
(GE Healthcare).
Statistical Methods—Because of the small sample size, the
BAJA study data were analyzed using theWilcoxon signed rank
nonparametric paired t test using GraphPad Prism Version 5
(La Jolla, CA). The COMP concentrations from the JoCo OA
cohort were log transformed to achieve a normal distribution
before analysis using a generalized linearmodel, the cumulative
logit model, controlling for age, gender, and race. As radio-
graphic data from the left and right joints of a personwere likely
to correlate, the intra-individual correlation was estimated in
the model as a variance component. The JoCo OA data repre-
sented in Fig. 4 were log transformed and analyzed by one-way
analysis of variance with a Bonferroni correction for multiple
comparisons. The cartilage extract data were analyzed either
with the Wilcoxon signed rank nonparametric paired t test for
paired data or using the nonparametric Mann-Whitney U test
for unpaired data.
RESULTS
Epitope Selection—We identified putative deamidation hot
spots within COMP using the algorithm developed by Robin-
son and Robinson (3). This algorithm used inputted crystal
structure and amino acid composition of COMP to predict Asn
residues susceptible to deamidation and gave an estimate of the
deamidation half-life for each individual Asn residue (CD
value  100 days) and half-life for net deamidation value (ID
value  100 days). As the crystal structure for human COMP
was not available at the time of this project, we used the two
partial rat Protein Data Bank structural files 1fbm (24) and 1vdf
(25). Both crystal structures span the amino-terminal region of
rat COMP between Gly27 and Gly72. Using the two rat terminal
structural files, we identified two Asn residues (amino acids 41
and 63) susceptible to deamidation, in human COMP desig-
nated Asn42 and Asn64, respectively (Table 2). Neither of these
residues has a particularly fast deamidation rate, with Asn41
predicted to have a deamidation half-life between 21 and 26
years and Asn63 between 39 and 50 years, making them ideal
markers for monitoring degradation of a long lived tissue such
as cartilage matrix degradation. We compared the sequence
alignment for a range of different species available in the NCBI
data base (www.ncbi.nlm.nih) and confirmed that the predicted
Asn deamidation hot spots were contained in human COMP
and conserved in a wide range of other animals (Table 2).
To determine whether the predicted deamidated sequences
occur in vivo, we performed LC-MS/MS analysis of Gdn-HCl
extracts from five articular cartilage specimens from three sub-
jects. We were unable to confirm the presence of the predicted
deamidation event atAsn42 in these samples.However, wewere
able to confirm the presence of the native Asn64 tryptic peptide
(64NTVMECDACGMQQSVCR) and the deamidated Asp64
peptide (64DTVMECDACGMQQSVCR) in normal hip, OA
hip, and OA knee cartilage (both remote and lesioned regions).
As we were able to determine peak intensities for both the
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Asp64 and Asn64 peptides within the same MS run, we calcu-
lated within sample ratios of D-COMP to native COMP. In all
five specimens, the native Asn64 peptide was more abundant
than the Asp64 deamidated peptide (by 83–330-fold) based on
intensities of mass spectroscopic traces, with a mean (S.D.)
intensity of 145,178  86,144 for the Asn64 peptide compared
with an intensity of 1,382  1,092 for the Asp64 deamidated
peptide (representing a mean 0.95% relative level of D-COMP
to native COMP).
Antibody Generation and Validation—To generate mAbs to
deamidated epitopes in COMP, mice were immunized with a
peptide containing Asp64 (TFLKD64TVMEC) found in
deamidated COMP. Using this approach, we expected to gener-
ate two classes of mAbs, those that recognized the deamidated
Asp64 residueandmAbs thatweredeamidation-independent, rec-
ognizing both the amidated and deamidated sequence. We iden-
tified 21 mAb clones that recognized the immunogen. To deter-
mine the specificities of these 21 clones, we compared their
immunoreactivity to four different BSA-conjugated COMP pep-
tides as follows: thedeamidatedAsp64 (TFLKD64TVMEC) immu-
nogen, native Asn64 (TFLKN64TVMEC), deamidated Asp42
(CELQETD42AALQ), and native Asn42 (CELQETN42AALQ)
(Fig. 1a). As anticipated, we identified the following two types
of mAbs using this approach: mAbs that appeared to be
deamidation-independent as they recognized both the Asn64
and Asp64 containing BSA constructs (clones 6-1A10, 6-3B3,
6-3B1, 6-3A1, 6-1G7, 6-1H12, 6-1H7, and 6-2A9), and
deamidation-specific clones (clones 6-1A12, 6-1A6, 6-1A8,
6-1A4, 6-1F9, 6-1B4, 6-3B5, 6-1H3, 6-3A5, 6-3B10, 6-1F8,
6-1H1, and 6-1C12). None of the 21 clones raised to the
Asp64 peptide bound the BSA-coupled Asn42 or Asp42 con-
trol peptides; the immunoreactivity of these control peptides
was confirmed by reactivity with the deamidation indepen-
dent mAb (5-3D4) raised specifically to the Asp42-contain-
ing peptide (Fig. 1a).
To confirm that the mAbs recognized COMP from human
cartilage and not just peptides, a subset of these mAbs was
screened by direct ELISA against COMP purified from human
hip cartilage pooled from two subjects (Fig. 1b) (generous gift
from V. Vilim (see Ref. 26)). All mAbs tested displayed higher
than background immunoreactivity to cartilage COMP. Of
note, the mAb preparations used in these validation experi-
ments were not purified so the apparent differences in
immunoreactivity could reflect mAb concentration rather
thanmAb affinity. In addition, the fact that the deamidation-
specific mAbs reacted to cartilage COMP suggested suffi-
cient sensitivity on the part of these mAbs to identify the
presence of deamidated Asp64 in COMP purified from
human articular cartilage.
For the further experiments in this study, we selected the
Asp64 deamidation-specific 6-1A12 mAb because it grew well
in culture andproduced a high yield ofmAb.The specificity and
affinity of the 6-1A12 mAb was confirmed through evaluation
of its binding to different coating concentrations of both the
native anddeamidatedBSApeptides (Fig. 1c). The 6-1A12mAb
had no affinity for the native Asn64-containing sequence but
instead had a high specificity for only the deamidated Asp64
COMP-containing peptide. To further confirm that the 6-1A12
mAb recognized COMP extracted from cartilage and not just a
COMP-specific peptide, we performed a reducedWestern blot
of OA hip cartilage Gdn-HCl extract (Fig. 2). The deamidation
specific 6-1A12 mAb detected a 110-kDa protein that corre-
TABLE 2
Species conservation of predicted deamidation hotspots in COMP
1Human; 2Rat; 3Mouse; 4Dog; 5Horse; 6Cattle; 7Chimpanzee; 8Pig; 9Red jungle fowl; 10Giant panda; 11Western clawed frog; 12Gray short-tailed opossum; sequence number-
ing based on human COMP.
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sponded to a band of similar molecular mass detected by the
established anti-COMP mAb 17-C10 (27) and that corre-
sponded to the size of monomeric COMP.
Decline in Serum Concentrations of D-COMP but Not Total
COMP after Joint Arthroplasty—To determine whether the
D-COMP epitope could be measured in biological fluid, we
FIGURE 1. Monoclonal antibody specificity of mAbs raised to the COMP-deamidated epitope Asp64. a, screening of mAbs against deamidated and native COMP
peptides. Two native COMP BSA-peptide constructs, Asn42 (BSA-CELQETN42AALQ) and Asn64 (TFLKN64TVMEC-BSA), and the corresponding two deamidated BSA
constructs, Asp42 (BSA-CELQETD42AALQ) and Asp64 (TFLKD64TVMEC-BSA), were coated onto 96-well plates. Hybridoma culture media were incubated with the coated
plates for 2 h before addition of goat anti-mouse alkaline phosphatase secondary antibody and ELISA development using OPD substrate. A negative control contain-
ing no primary antibody was included, and a mAb raised against CELQETD42AALQ was used to confirm immunoreactivity of the BSA-CELQET(N/D)42AALQ control
peptides. Screening yielded a total of eight deamidation-independent (immunoreactivity to Asn64 and Asp64) and 13 deamidation-dependent mAbs (preferential
immunoreactivity to Asp64). b, screening of mAbs against purified cartilage COMP. Purified COMP protein (a generous gift from V. Vilim) was coated onto 96-well plates.
Hybridoma culture media were incubated with the coated plates for 2 h before addition of goat anti-mouse alkaline phosphatase secondary antibody and ELISA
development using OPD substrate. A negative control containing no primary antibody and a positive control using the anti-COMP 17-C10 mAb were included. c, mAb
6-1A12 preferentially reacted against deamidated COMP peptide and not the native COMP sequence. To test the affinity of the 6-1A12 mAb for both native and
deamidated COMP, different concentrations of either the D-COMP Asp64 specific TFLKD64TVMEC-BSA or the native COMP-specific Asn64 TFLKN64TVMEC-BSA were
coated onto a 96-well plate in a direct ELISA, performed as for a. A standard curve with an appropriate dose response is generated for 6-1A12 and the deamidated
COMP Asp64-BSA construct; 6-1A12 did not recognize the native Asn64-BSA construct.
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developed a competitive ELISA using the 6-1A12 mAb and the
BSA-coupled deamidated COMP-specific (TFLKD64TVMEC)
construct as both the coating antigen and the assay standard. In
the BAJA study, serum (n  14) was collected before joint
replacement (pre-joint arthroplasty samples) and 6 months
after either hip (n  4) or knee (n  10) total arthroplasty. We
expected to observe a decrease in the serum concentrations of
biomarker after joint arthroplasty, thereby supporting in prin-
ciple a joint tissue source for the measured biomarker in the
serum. Six months after joint replacement, serum total COMP
concentration (1,513  457 ng/ml) was not significantly
changed (p  0.502) from baseline prior to joint replacement
(1,600  655 ng/ml) (Fig. 3a). However, we did observe a small
but significant (p  0.017) decrease in the serum concentra-
tions of D-COMP 6 months after joint replacement (578.6 
154 pg/ml) compared with baseline prior to joint replacement
(726 158 pg/ml) (Fig. 3b). Stratified by joint site, we observed
a small but nonsignificant decreasing trend for D-COMP fol-
lowing knee replacement (13% mean decline from 732  48
pg/ml prior replacement to 638  34 pg/ml 6 months post-
replacement) and a larger decreasing trend for D-COMP fol-
lowing hip replacement (39% mean decline from 711  108
pg/ml to 431  83 pg/ml post-replacement). There was mini-
mal change in total COMP stratified by joint site for knee (5%
mean decline from 1680  225 to 1593  166 ng/ml post-
replacement) or hip (6% mean decline from 1400  260 to
1316  26 ng/ml post-replacement).
Serum concentrations of D-COMP and total COMP were
reported on hip and knee OA severity, respectively. To further
investigate the utility of D-COMP as a novel biomarker for OA,
we measured D-COMP and total COMP in the JoCo OA sub-
sample of patients. This sample subset was derived from the
population-based JoCo study (16). The total subsample of 450
individuals included 898 nonreplaced knees and 896 nonre-
placed hips, graded for radiographic OA severity by KL grade.
For improved sensitivity, we developed and optimized (data not
shown) a sandwich ELISA using our deamidation-specific
6-1A12 mAb for capture and the 17-C10 total COMPmAb for
detection. Using linear regression analysis, we evaluated for an
age association of serumD-COMPand total COMP concentra-
tions in the 158 non-OA subjects defined as KL 0-1 for both
hips and knees. This subset ranged in age from 44 to 77 years
(mean  S.D. of 55.9  7.8 years). There was a significant but
minimal positive association of total COMP with age (p 
0.007, r2  0.045) but no association of D-COMP (p  0.90,
r20.001) with age (supplemental Fig. 1).
To determine how serum COMP levels changed with sever-
ity of OA, we analyzed the full JoCo 450 subjects using gener-
alized linear models (cumulative logit models) controlling for
the intra-individual correlation in themodel as a component of
variation, as well as age, gender, and race. Radiographic knee
OA was present with the following frequencies of KL knee OA
FIGURE 2. Western blot demonstrating D-COMP mAb binding to COMP
from Gdn-HCl extract of hip articular cartilage. Protein extracts were pre-
pared from osteoarthritic hip cartilage harvested from both an OA lesional
site and remote from the lesion in remote OA cartilage. Prior to SDS-PAGE
separation on a 10% gel, samples were dialyzed into PBS, protein levels deter-
mined, and 5 g of protein loaded per lane. Samples were separated under
standard conditions and transferred to nitrocellulose that was blocked with
3% milk proteins prior to mAb incubation and development with ECL
reagents. D-COMP was immunolocated with mAb 6-1A12 specific for deami-
dated COMP (left) and total COMP was immunolocated with mAb 17-C10
(right). For clarity, the membrane immunostained for total COMP was
exposed for a shorter time period (30 s), although the membrane immuno-
stained for D-COMP, due to it lower levels, required a longer exposure (5 min).
FIGURE 3. Serum D-COMP but not total COMP concentrations declined
following replacement of OA joints. Sera were obtained before and 6
months after joint arthroplasty in the BAJA cohort. Total serum COMP, mea-
sured by sandwich ELISA, and serum D-COMP, measured by competition
ELISA, were determined pre- and 6 months post-joint replacement for n  14
patents (nine knee and five hip replacements). mAb 6-1A12 was used for
D-COMP competition ELISA; for total COMP sandwich ELISA mAbs 16-F12
captured and biotinylated 17-C10 for detection. Significant differences were
determined using the paired nonparametric Wilcoxon signed rank test. Total
COMP was unchanged after joint replacement (a), and D-COMP declined sig-
nificantly (p  0.017) following joint replacement (b).
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severity grades: 535 KL0; 153 KL1; 115 KL2; 81 KL3; 14 KL4,
and two knee replacements. Radiographic hip OA occurred
with the following frequencies of severity: 73 KL0; 512 KL1; 287
KL2; 20 KL3; 4 KL4, and four hip replacements. Total COMP
and D-COMP were associated with age but not gender or race.
Independent of age, total COMP was significantly associated
with knee OAKL grade (p  0.0001) but not hip KL grade (p 
0.40). In contrast and independent of age, D-COMPwas signif-
icantly associated with hip OA KL grade (p  0.0001) but not
with knee OA KL grade (p  0.87). For knee OA, we also had
available the scores for radiographic OA features of joint space
narrowing and osteophyte. Total COMP was strongly associ-
ated with both knee joint space narrowing (p  0.0001) and
knee osteophyte (p  0.0001), whereas D-COMP was not. To
provide a graphic representation of the results, D-COMP val-
ues are shown in scatter plots stratified by knee and hip OA
status (Fig. 4). These data strongly suggest that the serum
D-COMP assay provides a new biomarker indicative of the
presence and severity of hip OA, whereas native nondeami-
dated or total COMP is an indicator of the presence and severity
of knee OA.
Concentrations of D-COMP in Hip Cartilage Exceeded Those
of Knee Cartilage—To better understand the results from the
JoCo OA cohort and the relationship between D-COMP and
hip OA, we investigated the amount of D-COMP and total
COMP in Gdn-HCl-extracted soluble protein from OA hip
(n  12) and knee cartilage samples (n  16) collected as waste
surgical tissue at the time of joint arthroplasty.
We comparedD-COMPand total COMP levels from regions
of hip and knee cartilages adjacent to OA lesions and from
regions of the same joint remote from the OA lesion. We also
evaluated the ratio of D-COMP/total COMP as a measure free
from confounding by extraction efficiencies and dialysis varia-
tions. For comparison, we also included age-matched non-OA
hip (n  4, mean age 73.5 years 6.9, range 67–82 years) and
knee (n  7, mean age 60.6 years 14.5, range 52–83 years)
cartilage collected as waste trauma or cadaveric tissue.
Total COMP in cartilage did not vary by joint site (lesion or
remote) or joint group (knee or hip) (Fig. 5a). In contrast,
D-COMP did vary by joint site. D-COMP was significantly
higher in hip versus knee lesion cartilage (mean  S.D., 9.26 
7.30 and 1.57  2.01 ng of D-COMP/g of protein extracted,
respectively, p 0.0003), and a similar but not significant trend
was observed for D-COMP in hip remote versus knee remote
cartilage (mean  S.D., 3.72  5.10 and 0.96  0.68 ng of
D-COMP/g of extracted protein, respectively, p  0.14) (Fig.
5b). D-COMP was significantly higher in the hip lesional carti-
lage compared with the hip remote cartilage (p  0.007) and
compared with non-OA hip cartilage (p  0.02) and remote
knee cartilage (p  0.0001) as follows: mean  S.D. of 9.26 
7.3, 3.72 5.06, 0.47 0.17, and 0.96 0.68 ng ofD-COMP/g
of extracted protein, respectively. There was no significant dif-
ference in D-COMP levels between non-OA hip and knee car-
tilage samples. These data confirm that theD-COMP epitope is
more abundant in OA hip than either OA knee cartilage or
non-OA cartilage and is enriched at the site ofOA lesions in the
hip.
To better understand the turnover of COMP at the different
sites, we evaluated the ratio of agedD-COMP/total COMP (Fig.
5c). The D-COMP/total COMP ratio was highest in hip OA
FIGURE 4. Association of serum D-COMP with hip OA severity and total
COMP with knee OA severity in the JoCo OA cohort samples. Sera and x-rays
(of both hips and knees) were obtained for 450 subjects from the JoCo OA cohort.
X-rays were read for OA severity status as defined by KL grade (0–4 scale) with OA
being defined as KL grade 2. For the purposes of this analysis, the KL scores
were summed for both hips or both knees (total possible range of 0–8). Serum
levels for both D-COMP and total COMP were determined, and the data natural
log transformed for statistical purposes. The data are represented as scatter plots
showing the mean  S.D. ln D-COMP and ln total COMP for non-OA subjects
(KL0–1), early OA (KL2 and KL3), and for advanced OA (KL4). a demonstrates
significant increase in D-COMP with hip OA severity, and b demonstrates no sig-
nificant change in D-COMP with knee OA severity. c demonstrates no significant
change in total COMP with OA hip severity, and d demonstrates significant
increase in total COMP with knee OA severity. For each KL group (0–1, 2, 3, 4)
the frequencies were n  48, 200, 99, and 102 for hip OA, and n  46, 199, 99, and
102 for knee OA. Subjects were excluded when COMP was not quantifiable as
follows: one subject for D-COMP and four subjects for total COMP. Significance
was determined using a one-way analysis of variance with a Bonferroni correc-
tion for multiple comparisons.
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lesional cartilage and higher at the hip lesion versus any of the
other regions, namely versus the hip remote (p  0.001), knee
remote (p  0.0001), or knee lesion (p  0.0003) cartilage
(mean  S.D., 29.96  38.18 hip lesion, 9.58  18.59 hip
remote, 1.30  0.78 knee remote, and 2.47  2.84 knee lesion).
We also observed a significantly higher D-COMP/total COMP
ratio between hip remote and knee remote cartilage (mean 
S.D., 9.58  18.59 and 1.30  0.78 D-COMP/total COMP,
respectively, p  0.017).
Relative to non-OA hip cartilage, hip lesionOA cartilage had
significantly higher (p  0.012) extractable concentrations of
D-COMP as a proportion of total COMP (mean  S.D., 1.84 
0.5 and 2.47 2.1 respectively, Fig. 5c). As D-COMP has a long
residence time in cartilage, it is conceivable that the differences
observed between hip and knee OA D-COMP levels could be
due to differential cross-linking of D-COMP to the collagen
matrix preventing release from the cartilage in kneeOA.To test
this, we performed LC-MS/MS analysis of extracts from
lesional regions of three age-matched cartilage samples as fol-
lows: anOAhip (72 years), anOA knee (75 years), and a normal
hip (76 years). Gdn-HCl extraction of the cartilage samples
yielded a soluble protein fraction and a paired insoluble fraction
that was subjected to trypsin digestion and mass spectroscopic
analysis. The tryptic peptide (64NTVMECDACGMQQSVR)
corresponding to the native COMP sequence was present in all
samples. As expected,more native COMPpeptide was found in
the Gdn-HCl-soluble fraction than in the insoluble cartilage
residua (see supplemental Table 2). However, wewere only able
to identify the deamidated peptide (64DTVMECDACG-
MQQSVR), corresponding to the D-COMP epitope, in the
Gdn-HCl soluble fraction and not in the insoluble fraction.
Although this result does not absolutely exclude its presence
in the insoluble fraction, it suggests that the deamidated
epitope is not preferentially tethered in cartilage. The ratios
of the intensity of the deamidated/native COMP peptide in
the soluble protein fractions confirmed the abundance of
extractable deamidated COMP from hip compared with
knee cartilage (supplemental Table 2).
As we have no evidence to suggest preferential cross-linking
in the OA knee cartilage, we believe that these results suggest
lower turnover and older proteins in hip OA lesions. Interest-
ingly, we observed the reverse in knee OA. Relative to non-OA
knee cartilage (mean  S.D., 6.73  4.9), knee OA had signifi-
cantly lower concentrations of D-COMP as a proportion of
total COMP at both remote (p  0.004, 2.47  2.8) and lesion
(p  0.009, 1.30  0.9) sites. These results suggest that the
COMP in knee OA cartilage is newer and turning over faster.
Non-OA hip and knee cartilages were statistically similar with
respect to D-COMP as a proportion of total COMP suggesting
that non-OA hip and knee cartilages have similar turnover and
that the joint response to OA is quite different by hip versus
knee joint site. Taken together, these data are consistent with aFIGURE 5. Enrichment of D-COMP in hip cartilage and OA lesion sites.Soluble proteins were extracted from cartilage using 4 M Gdn-HCl before
buffer exchange into PBS to allow further analysis. Total COMP (a) and
D-COMP (b) were measured by sandwich ELISA and normalized to total pro-
tein to correct for variations in the extraction and dialysis efficiency. The ratio
of D-COMP/total COMP (c) was calculated as a measure that is independent of
technical variation due to variation in protein extraction and dialysis effi-
ciency. Data were plotted on a logarithmic scale for clarity, and statistical
differences were determined on nonlogarithmically transformed data using
nonparametric statistics. For paired samples (remote and lesion within a
joint), the Wilcoxon signed rank test was used; for nonpaired samples (hip and
knee joint comparisons) intergroup significance was determined using the
nonparametric Mann-Whitney U test. D-COMP and the D-COMP/total COMP
ratio were higher in hip than knee cartilages and higher in hip OA lesions than
in hip cartilage remote from lesions.
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model positing lower rates of cartilage COMP synthetic repair
in hip OA, and particularly at hip OA lesions, compared with
normal hip and non-OA and OA knee.
DISCUSSION
To our knowledge, this is the first demonstration that a car-
tilage extracellular matrix component, measured systemically,
demonstrated specificity for OA severity at a particular joint
site. We believe this reflects a fundamental underlying differ-
ence between hip and knee cartilage turnover and repair
responses in OA. We observed no association between
D-COMP serum levels and chronological age in non-OA sub-
jects. This is not surprising as the half-life for generating our
epitope is predicted by the Robinson and Robinson algorithm
(3) to be between 39 and 50 years. Assuming COMP has a turn-
over rate similar to the predicted half-life of 25 years for aggre-
can (9), then accumulation of D-COMP with age in healthy
cartilage would be prevented by normal cartilage turnover.
We demonstrated in our post-joint arthroplasty BAJA study
of 14 patients, a significant decrease in the concentrations of
our new and novelD-COMPbiomarker after the removal of the
affected arthritic joints. The greatest decrease in D-COMPwas
observed for the hip, although the knee showed a much more
modest decrease in D-COMP levels. As OA does not usually
affect only a single joint, and even normal joint turnover would
be expected to contribute to the overall serumD-COMP levels,
replacement of a single joint led, as expected, to a decline but
not a disappearance of D-COMP from the serum. In contrast,
we did not observe any significant decrease in total COMP lev-
els after joint arthroplasty. These results with total COMP are
consistent with observations made previously by Sharif et al.
(28) who demonstrated that total COMP actually increased,
rather than decreased, for at least 6 months following joint
replacement. Other reports have demonstrated total COMP
production by osteoblasts (29) and the potential for elevated
total COMPduring the period of reactive bone repair following
joint arthroplasty.We believe that D-COMPmeasured system-
ically reflects degradation of mature aged cartilage; this is in
contrast to native or total (the majority of which is native non-
deamidated) COMP epitope in the systemic circulation that
we posit reflects, in part, high turnover of newly synthesized
tissue, or so-called “frustrated repair” (30), or new COMP
production from a reparative bone response occurring after
joint replacement.
In the much larger JoCo OA cohort, we were better able to
refine our understanding of the utility of D-COMP as a bio-
marker. In this cohort, we observed that D-COMP was highly
significantly correlated with hip OA severity but not with knee
OA severity. We also observed that total COMP was strongly
associated with knee OA but not with hip OA severity. Of note,
in the JOCO cohort sample, the greatest increase in serum
D-COMP occurred with the transition from the KL0-1 to the
KL2 level of hipOA severity. This would suggest that D-COMP
may be of particular value as an early indicator of hip pathology
and OA.
The association of total COMP with knee OA progression is
well established (31–35). A few studies have investigated total
COMP in the setting of hip OA (36–39). Three studies
observed that higher levels of baseline COMP predicted the
development of hip radiographic OA (36, 38, 39). One of these
studies suggested that high baseline COMP levels were associ-
ated with a reduction in radiographic progression (36). One
small study found an association between hip JSN and increas-
ing serumCOMP levels over a 1-year follow up period (37), and
another larger study foundno association of total serumCOMP
with hip OA but a significant association with knee OA osteo-
phyte (40). We believe the unique ability of our D-COMP bio-
marker to correlate with hip but not knee OA severity demon-
strates the utility and value of studying post-translational
modifications in cartilage proteins as biomarkers of OA.
To better understand the underlying biological basis for
D-COMP as a hip OA but not knee OA biomarker, we investi-
gated the concentrations of D-COMP in cartilage extracts from
OA hips and knees. We hypothesized that D-COMP would be
increased in cartilage with a low turnover rate and that biolog-
ically older tissues would have a higher D-COMP/total COMP
ratio. We observed a significantly higher mean D-COMP/total
COMP ratio in OA hip cartilages compared with OA knee car-
tilages. Total COMP concentrations between hip and knee car-
tilage were not significantly different confirming that the dif-
ferences observed in the ratios were due to a higher proportion
of D-COMP in hip cartilage. These data strongly suggest that
COMP, and by inference the cartilage extracellularmatrix in an
OA hip joint, is turned over (net of catabolism and anabolism)
at a much lower rate than cartilage in an OA knee joint. Con-
versely, this would indicate that knees are more robust at
repairing ongoing degradation than hips.
In the hip, we also observed significantly higher concentra-
tions of D-COMP and D-COMP/total Comp ratio in lesional
OA cartilage when compared with remote regions. The ele-
vated concentrations of D-COMP at hip OA lesions further
support the serum biomarker observation that D-COMP was
associated with hip OA. Moreover, this suggests that lesional
cartilage is biologically older than the cartilage remote from the
lesion and is consistent with lower rates of COMP synthesis at
sites of hip OA lesions. For comparison, we included non-OA
and age-matched cartilage collected as cadaveric tissue or
shortly after trauma at the time of surgical repair. We found no
significant difference between non-OA hip and knee cartilage
for either D-COMP or total COMP. However, the D-COMP/
total COMP ratio of OA lesional hip cartilage was significantly
higher than non-OA cartilage suggesting that cartilage at the
lesion is older. In contrast, we observed the opposite in the
knee, with significantly lower than normal D-COMP/total
COMP ratios in the OA tissue. As we were unable to find any
evidence of enhanced cross-linking of older COMP in the knee
OA cartilage, we believe these data support the hypothesis that
serum D-COMP reflects cartilage turnover and that hip OA
tissue is older (low repair response) than non-OA hip, whereas
the knee OA tissue is younger (high repair response) than
non-OA.
Although higher concentrations of D-COMP at hip lesions
could potentially be explained by accelerated D-COMP pro-
duction, we believe this to be unlikely as there was no evidence
for accelerated production of D-COMP at knee OA lesions,
whichwould be expected to be exposed to very similar catabolic
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conditions during cartilage loss. Radiolabeled proteoglycan
studies in cartilage have shown that cartilagematrix turnover is
greatest in the superficial zone whereas the matrix becomes
older and the protein turnover rate decreases deeper into the
cartilage (41). Therefore, we favor a model wherein gradual
erosion of the cartilage at hip OA lesions leads, in the relative
absence of synthetic repair, to the loss of the superficial and
medial cartilage layers, leaving behind the older deeper zones.
In summary, we were able to predict a deamidation event in
the cartilagematrixmolecule COMP, demonstrate its presence
in human cartilage, produce specificmAbs to thismodification,
and develop an ELISA to study its utility as a biomarker in OA.
We identified a D-COMPmodification that is not only a novel
biomarker in OA but also a biomarker with specificity for hip
OA, which, to the best of our knowledge, is the first OA bio-
marker specific to a particular joint site. Based upon our studies
of COMP in cartilage, we believe we can explain the specificity
of our D-COMP biomarker through a lower COMP protein
synthesis in hip OA when compared with knee OA and higher
rate of knee cartilage extracellular matrix turnover. The clear
differences in D-COMP concentrations at remote OA hip and
knee cartilage are consistent with different biological aging
rates in these two large joint sites in OA due in part to less
COMP synthesis in hips than knees. Hip OA cartilage lesions,
in particular, were differentially enriched for D-COMP. This is
compatible both with loss of the more rapidly regenerating
superficial cartilage layers and inadequate COMP synthesis,
resulting in biologically older remaining deep layers of hip OA
cartilage.We believe that D-COMPwarrants further study as a
marker of hip disease to determine more clearly its utility in a
patient setting, although currently we would envision its use as
a longitudinal marker to follow disease progression within a
subject. Examination is also warranted to determine its ability
to detect occult or pre-radiographic hip disease.
Acknowledgments—We thank David Quintana for assistance with
the BAJA sample collection. We also thank the Duke Proteomics Core
Facility (Drs. Erik Soderblom and Arthur Moseley) for their expert
assistance andDr. Vladimir Vilim for the gift of 17-C10 antibody and
purified COMP from human cartilage.
REFERENCES
1. Cloos, P. A., and Christgau, S. (2002) Nonenzymatic covalent modifica-
tions of proteins. Mechanisms, physiological consequences, and clinical
applications.Matrix Biol. 21, 39–52
2. McCudden, C. R., and Kraus, V. B. (2006) Biochemistry of amino acid
racemization and clinical application to musculoskeletal disease. Clin.
Biochem. 39, 1112–1130
3. Robinson, N. E., and Robinson, A. B. (2004)Molecular Clocks: Deamida-
tion of Asparaginyl and Glutaminyl Residues in Peptides and Proteins, pp.
1–419, Althouse Press, Cave Junction, OR
4. Daumy, G. O., Wilder, C. L., Merenda, J. M., McColl, A. S., Geoghegan,
K. F., andOtterness, I. G. (1991) Reduction of biological activity of murine
recombinant interleukin-1 by selective deamidation at asparagine 149.
FEBS Lett. 278, 98–102
5. Teshima, G., Porter, J., Yim, K., Ling, V., and Guzzetta, A. (1991) Deami-
dation of soluble CD4 at asparagine 52 results in reduced binding capacity
for the HIV-1 envelope glycoprotein gp120. Biochemistry 30, 3916–3922
6. Deverman, B. E., Cook, B. L., Manson, S. R., Niederhoff, R. A., Langer,
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